Therapies and Procedures
AtriCure offers a robust portfolio of products used in some of the most complex therapies and procedures.
- Healthcare Professionals
- Patients & Caregivers
- About AtriCure
First Patient Treated in LeAAPS Clinical Trial
Safety & effectiveness study to evaluate if prophylactic left atrial appendage exclusion reduces occurrence of ischemic stroke or systemic embolism in cardiac surgery patients with elevated risk of stroke and no history of atrial fibrillation
Top Workplaces 2023
Ready to work at a Top Workplace?
Hybrid AF Therapy with EPi-Sense System
Minimally Invasive Ablation Therapy for the Treatment of Advanced Atrial Fibrillation
Providing Several Months of Post-Operative Pain Relief
Cryo Nerve Block Therapy uses a unique freezing method to temporarily block pain signals from the nerves.
We are Humbled by Our Talented Board and Employees!
Our responsibility to advance Diversity, Equity, and Inclusion is driven by a passionate belief that diverse thinking, skills, and experience bring the best outcome to our work as we innovate products and therapies that improve patients’ lives.
0
Patients Served with Ablation Worldwide
0
AtriClip Devices Sold Worldwide
NEWS
AtriCure Reports Third Quarter 2023 Financial Results
REDUCING GLOBAL AFIB
What is Afib, and how does it affect heart performance?
CAREERS
Interested in joining our mission to reduce the global Afib epidemic?
CLINICAL EVIDENCE
Learn about active clinical trials and trials with results
PM-CANLAM-2654A-0525-G
© 2023 Atricure, Inc. All Rights Reserved.
Drs. Peter Tsai and @drdavidsingh from The Queens Medical Center performed their first Hybrid Convergent Procedure! Combining epicardial ablation and endocardial RF ablation, EPs and Cardiac Surgeons are teaming up in the fight against Afib. https://bit.ly/HybridAFTherapy #EPeeps
Drs. Peter Tsai and @drdavidsingh from The Queens Medical Center performed their first Hybrid Convergent Procedure! Combining epicardial ablation and endocardial RF ablation, EPs and Cardiac Surgeons are teaming up in the fight against Afib. https://bit.ly/HybridAFTherapy #EPeeps
LAAM is now a Class 1A recommendation per the 2023 ACC/AHA/ACCP/HRS Guidelines of Diagnosis and Management of #Afib. With 20+ years of innovation and 500,000+ global device implants, we're proud to play a role in advancing Afib treatment. Full guidelines: https://bit.ly/3uCqeAG#LAAM #CardioTwitter
LAAM is now a Class 1A recommendation per the 2023 ACC/AHA/ACCP/HRS Guidelines of Diagnosis and Management of #Afib. With 20+ years of innovation and 500,000+ global device implants, we're proud to play a role in advancing Afib treatment. Full guidelines: https://bit.ly/3uCqeAG#LAAM #CardioTwitter
The Encompass Clamp is the latest RF technology for surgical ablations. We explored its capabilities and how it can aid doctors at #ICC2023. Thanks to those who joined us! To delve deeper into surgical ablations, visit: https://bit.ly/361llVN @ISCAScoronary #CardioTwitter
The Encompass Clamp is the latest RF technology for surgical ablations. We explored its capabilities and how it can aid doctors at #ICC2023. Thanks to those who joined us! To delve deeper into surgical ablations, visit: https://bit.ly/361llVN @ISCAScoronary #CardioTwitter
The 2023 ACC/AHA/ACCP/HRS Guidelines for Diagnosis and Management of #Afib have been released! Left atrial appendage management has been upgraded to Class 1A and Hybrid AF™ Therapy has been added as a Class 2B recommendation. See the full guideline at https://bit.ly/3uCqeAG #LAAM #CardioTwitter #Epeeps
The 2023 ACC/AHA/ACCP/HRS Guidelines for Diagnosis and Management of #Afib have been released! Left atrial appendage management has been upgraded to Class 1A and Hybrid AF™ Therapy has been added as a Class 2B recommendation. See the full guideline at https://bit.ly/3uCqeAG #LAAM #CardioTwitter #Epeeps
social media channels to keep updated on the latest at AtriCure.